Navigation Links
BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
Date:3/23/2009

NEW HAVEN, Conn. and TORONTO, March 23 /PRNewswire/ -- BioRelix, pioneers in the discovery and development of Riboswitch based therapeutic agents, and Dalton Medicinal Chemistry have jointly announced an expansion and renewal of their exclusive worldwide collaboration and agreement to discover and develop new therapeutics.

Dalton Medicinal Chemistry will apply their proprietary insights to the design and synthesis of new classes of compounds against selected Riboswitch targets. BioRelix will advance these compounds with their cutting edge array of biological assays and thorough knowledge of Riboswitch drug discovery and development.

Brian Dixon, BioRelix CEO commented, "We are pleased to have the opportunity to expand and renew our productive relationship with the creative team at Dalton Medicinal Chemistry. We are confident their expertise, insights and commitment to high quality medicinal chemistry, coupled with our propriety and leading position on Riboswitches, will continue to deliver value in important new medicines."

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are delighted to work further with BioRelix in the discovery and development of much needed new anti-infective agents. The team at BioRelix has clearly established a remarkably innovative and fundamentally groundbreaking approach to anti-infectives and we are pleased to be with them at the forefront of this medicinal chemistry and drug discovery."

About BioRelix:

BioRelix, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective product candidates based on novel patented RNA targets, termed Riboswitches, which were identified by the laboratory of BioRelix co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University. BioRelix investors include CHL Medical Partners, Novartis Venture Fund, Aisling Capital, New Leaf Venture Partners, Elm Street Ventures and Alexandria Real Estate Equities.

About Dalton Medicinal Chemistry:

Dalton Medicinal Chemistry is a drug discovery company focused on the design, synthesis and advancement of new chemical entities in partnership with Biotech and Pharma.


'/>"/>
SOURCE Dalton Medicinal Chemistry
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals
2. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
3. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
4. BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
5. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
6. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
7. Acesys and Provid Announce Alliance for Medicinal Chemistry Services
8. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
9. MS Drug Development Agreement Based on WEHIs Medicinal Chemistry
10. Neptune Technologies expands into medicinal markets in Asia Pacific
11. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):